| Date |
Subject |
Media |
| 2025-08-12 |
Exclusive Interview with Mobisnet Technology: MIT Medical Robots Target the Smart Care Market
|
Entering the era of smart healthcare, what kind of enterprise can truly deliver flexible, clinically relevant solutions to medical institutions? The answer might surprise you — a software company originally focused on developing government tax systems. |
| 2025-08-12 |
Phison’s aiDAPTIV+ Enters Medical Field in Partnership with Hsinchu MacKay Memorial Hospital
|
Phison Electronics and Hsinchu MacKay Memorial Hospital held a press conference on the 28th to unveil the results of their collaboration, officially launching an on-premise generative AI system. This marks the hospital as one of the first medical institutions in Taiwan to deploy and operate a large language model (LLM) trained and inferenced entirely in-house. The event featured a live demonstration of the system generating real-time patient consultation records, with plans to gradually roll it out across the entire MacKay healthcare network. |
| 2025-08-12 |
Exclusive Interview with Brain Navi: Secures U.S. 510(k) Clearance, Countdown to IPO Begins
|
Following the successful attainment of U.S. FDA 510(k) clearance for its brain surgery robot in May 2025, Taiwanese startup Brain Navi officially launches its countdown to IPO, aiming to list on the capital market in 2026. This will mark Brain Navi as Taiwan’s first company to enter the advanced surgical robot field with an independent brand. |
| 2025-08-12 |
Orient Europharma Group’s Subsidiary Orient Pharma Set to List on OTC, Plans to Launch New Alzheimer’s Drug
|
Orient Europharma Group’s promising subsidiary Orient Pharma is scheduled to be listed on the Taipei OTC market in late August, with a tentative underwriting price of NT$28.04. Orient Pharma held a pre-OTC performance briefing on July 29. General Manager Chun-Tung Huang stated on July 28 that Orient Pharma focuses on three major technology platforms and is actively investing in core areas such as cardiovascular and central nervous system diseases. The company currently has three marketed drugs and plans to launch four new products, including an anti-Alzheimer’s drug, over the next four years starting this year. |
| 2025-08-12 |
HCMED INNOVATIONS Reaches Breakthrough Milestone with FDA Approval for Innovative Breath-Activated Nebulizer
|
HCMED INNOVATIONS, specializing in inhalation drug-device combination CDMO products, announced that its breath-activated nebulizer AdheResp has recently received U.S. FDA 510(k) clearance. AdheResp is the world’s first FDA-cleared breath-activated nebulizer with built-in connectivity, and currently the only advanced nebulizer device with mass production capacity to support pharmaceutical clients’ clinical trials. |
| 2025-08-12 |
Tanvex BioPharma’s Biosimilar Drug Enters U.S. Market
|
Tanvex BioPharma-KY announced yesterday (25th) that since forming a strategic alliance with the Bora Group in January this year, it will now operate under the CDMO business brand “Bora Biologics” starting this week. Tanvex Chairman Bobby Sheng stated that the company’s first biosimilar drug, NYPOZ (reference original drug: Neupogen, a leukocyte growth factor), is set to officially launch in the U.S. market in the second half of this year. Additionally, the newly added 2,000-liter production line at the San Diego facility is scheduled to begin operations in the first quarter of next year. |
| 2025-08-12 |
Elixiron Immunotherapeutics’ New Drug EI-1071 Gains International Recognition
|
Refusing to let foreign pharmaceutical companies take the lead, Elixiron Immunotherapeutics is developing Enrupatinib (code-named EI-1071), a microglia-modulating drug that targets brain immune regulation, primarily for treating Alzheimer’s disease. This novel drug has been recognized by the Global Neurodegeneration Proteomics Consortium, founded by Bill Gates, and has currently advanced into Phase II clinical trials. |
| 2025-08-12 |
CRDMO National Team’s New Factory to Mass Produce 13 Million mRNA Vaccine Doses Annually
|
The government-initiated CRDMO (Contract Research, Development, and Manufacturing Organization) national team—Taiwan Bio-Manufacturing Corporation (TBMC)—announced on the 25th that its GMP facility in Zhubei is expected to be completed by the end of this year. The factory will undergo validation in the first quarter of next year and begin production in the second quarter, with an annual capacity of 13 million mRNA vaccine doses. This supports the government’s “National Security Vaccine Resilience” plan and aims to establish Asia’s most advanced nucleic acid drug manufacturing hub. |
| 2025-08-12 |
BioPhoenix Secures U.S. Up Therapeutics License to Develop Novel Proteasome Inhibitor Against Cancer
|
BioPhoenix, a subsidiary of San Fu Chemical’s San Fu Biotech, announced on the 24th that it has signed a licensing agreement with U.S.-based innovative drug developer Up Therapeutics. BioPhoenix has acquired global development, manufacturing, and commercialization rights for Up284, a first-in-class small molecule drug targeting solid tumors such as ovarian cancer. Both parties plan to submit an IND application and initiate Phase 1 clinical trials within the next 18 months. |
| 2025-08-12 |
Asia Pathogenomics Expands into Japan, Marking Global Milestone for Taiwan’s Leading Infectious Disease Diagnostics Company
|
Asia Pathogenomics Co., Ltd. has officially established a Japanese subsidiary, APGアジア準訳ジャパン株式会社, in Tokyo as a key stepping stone for its expansion into the broader Asian market. The move aims to bring the company closer to Japan’s clinical needs while accelerating the application of metagenomic next-generation sequencing (mNGS) in infectious disease diagnostics, and deepening partnerships across both the medical and industrial sectors. |
